| 中国晚期肾癌靶向治疗的现状 |
| |
| 引用本文： | 马建辉. 中国晚期肾癌靶向治疗的现状[J]. 中国肿瘤临床, 2017, 44(24): 1223-1225. DOI: 10.3969/j.issn.1000-8179.2017.24.918 |
| |
| 作者姓名： | 马建辉 |
| |
| 作者单位： | 国家癌症中心/中国医学科学院北京协和医学院肿瘤医院（北京市 100021） |
| |
| 摘 要： | 肿瘤分子靶向治疗是在肿瘤分子生物学的基础上，以肿瘤相关的分子作为靶点，利用靶分子特异制剂或药物进行治疗。从2006年9月索拉非尼在中国上市，晚期肾癌的治疗进入靶向治疗时代已经走过了11年的历程。本综述主要通过回顾肿瘤分子靶向治疗的发展历程，探讨VEGF抑制剂治疗晚期肾癌的疗效，思考临床中遇到的问题，提出晚期肾癌靶向治疗的建议。
|
| 关 键 词： | 晚期肾癌 靶向治疗 现状 |
| 收稿时间： | 2017-08-11 |
Current status of targeted treatment for advanced renal carcinoma in China |
| |
| Affiliation: | National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China |
| |
| Abstract: | Targeted treatment for tumors is based on the molecular biological aspects of a tumor.Identifying tumor-associated molecules as targets and then creating molecular preparations based on these targets is the goal of drug treatment and targeted therapy. Treatment for advanced renal carcinoma has evolved since the era of targeted therapy began eleven years ago when sorafenib was approved in China in September, 2006.This article reviews the development of molecular targeted treatment for tumors, discuss the efficacy of vascular endothelial growth factor (VEGF) inhibitors for the treatment of advanced renal carcinoma, evaluate the problems arising from clinical experiences, and put forward some suggestions for targeted treatment of advanced renal carcinoma. |
| |
| Keywords: | |
|
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载全文 |
